Form 4: Adaptive Bio CSO Sells Shares for Tax Obligations

Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 470,266 shares of common stock to cover tax withholding obligations related to RSU and performance share unit vesting.

Summary

• Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (ADPT), reported two transactions involving the sale of common stock.
• On March 11, 2026, Robins sold 140,666 shares of common stock at a price of $13.17 per share.
• This initial sale was mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) and was not a discretionary trade.
• On the same date, Robins executed a second sale of 329,600 shares of common stock, also at $13.17 per share.
• This second transaction was similarly mandated to cover tax withholding obligations linked to the vesting of performance share units and was not a discretionary trade.
• The total number of shares sold across both transactions amounts to 470,266 shares.
• Following these transactions, Robins directly beneficially owns 1,522,058 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales were non-discretionary and solely for tax purposes related to equity award vesting, providing no new insight into management's confidence or the company's operational performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transactions represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs and performance share units.
• These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a standard practice for executives receiving equity compensation. These non-discretionary sales are typically executed to satisfy tax liabilities upon the vesting of stock awards and are generally not interpreted as an indicator of management's sentiment regarding the company's future prospects, unlike open market discretionary sales.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a routine event and does not typically indicate a change in the company's fundamental value or the insider's long-term view.
• Employees: The vesting of RSUs and performance share units indicates the ongoing operation of the company's equity incentive plans, which are a common component of executive compensation.

Key Dates

Recommendation

The reported transactions are non-discretionary 'sell to cover' sales for tax obligations related to equity vesting, which are routine and do not reflect a change in the insider's investment sentiment or the company's fundamentals. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information to alter an existing investment thesis.

Keywords

Adaptive Biotechnologies, ADPT, Form 4, insider transaction, share sale, equity compensation, tax withholding, RSU, performance share units, Harlan S Robins